dr. J.C. Oosterwijk

No picture available
j.c.oosterwijk umcg.nl


  1. 2016
  2. 2015
  3. Castro, E., Jugurnauth-Little, S., Karlsson, Q., Al-Shahrour, F., Pineiro-Yanez, E., Van de Poll, F., ... IMPACT Study (2015). High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Annals of Oncology, 26(11), 2293-2300. https://doi.org/10.1093/annonc/mdv356
  4. Saadatmand, S., Obdeijn, I-M., Rutgers, E. J., Oosterwijk, J. C., Tollenaar, R. A., Woldringh, G. H., ... Tilanus-Linthorst, M. M. (2015). Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). International Journal of Cancer, 137(7), 1729-1738. https://doi.org/10.1002/ijc.29534
  5. Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., ... CIMBA Consortium (2015). Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 313(13), 1347-1361. https://doi.org/10.1001/jama.2014.5985
  6. Jhuraney, A., Velkova, A., Johnson, R. C., Kessing, B., Carvalho, R. S., Whiley, P., ... ENIGMA Evidence-Based Network (2015). BRCA1 Circos: a visualisation resource for functional analysis of missense variants. JOURNAL OF MEDICAL GENETICS, 52(4), 224-230. https://doi.org/10.1136/jmedgenet-2014-102766
  7. Kuchenbaecker, K. B., Ramus, S. J., Tyrer, J., Lee, A., Shen, H. C., Beesley, J., ... Consortium Invest Modifiers BRCA1 (2015). Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), 164-171. https://doi.org/10.1038/ng.3185
  8. Peterlongo, P., Chang-Claude, J., Moysich, K. B., Rudolph, A., Schmutzler, R. K., Simard, J., ... kConFab Investigators (2015). Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 24(1), 308-316. https://doi.org/10.1158/1055-9965.EPI-14-0532
  9. 2014
  10. Vos, J. R., Teixeira, N., van der Kolk, D. M., Mourits, M. J. E., Rookus, M. A., van Leeuwen, F. E., ... Hereditary Breast and Ovarian Cancer Research Group Netherlands (2014). Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 23(11), 2482-2491. https://doi.org/10.1158/1055-9965.EPI-13-1279
  11. Bancroft, E. K., Page, E. C., Castro, E., Lilja, H., Vickers, A., Sjoberg, D., ... IMPACT Collaborators (2014). Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 66(3), 489-499. https://doi.org/10.1016/j.eururo.2014.01.003
  12. Brohet, R. M., Velthuizen, M. E., Hogervorst, F. B. L., Meijers-Heijboer, H. E. J., Seynaeve, C., Collee, M. J., ... HEBON Resource (2014). Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. JOURNAL OF MEDICAL GENETICS, 51(2), 98-107. https://doi.org/10.1136/jmedgenet-2013-101974
  13. 2013
  14. Saadatmand, S., Tilanus-Linthorst, M. M. A., Rutgers, E. J. T., Hoogerbrugge, N., Oosterwijk, J. C., Tollenaar, R. A. E. M., ... de Koning, H. J. (2013). Cost-Effectiveness of Screening Women With Familial Risk for Breast Cancer With Magnetic Resonance Imaging. Jnci-Journal of the national cancer institute, 105(17), 1314-1321. https://doi.org/10.1093/jnci/djt203
  15. Tilanus-Linthorst, M. M. A., Lingsma, H. F., Evans, D. G., Thompson, D., Kaas, R., Manders, P., ... Steyerberg, E. W. (2013). Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. International Journal of Cancer, 133(1), 156-163. https://doi.org/10.1002/ijc.28014
  16. Bojesen, S. E., Pooley, K. A., Johnatty, S. E., Beesley, J., Michailidou, K., Tyrer, J. P., ... Genetic Modifiers Canc Risk BRCA1 (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 45(4), 371-384. https://doi.org/10.1038/ng.2566
  17. 2012
  18. Saadatmand, S., Rutgers, E. J. T., Tollenaar, R. A. E. M., Zonderland, H. M., Ausems, M. G. E. M., Keymeulen, K. B. M. I., ... Tilanus-Linthorst, M. M. A. (2012). Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer, 12, [440]. https://doi.org/10.1186/1471-2407-12-440
  19. Hilbers, F. S., Wijnen, J. T., Hoogerbrugge, N., Oosterwijk, J. C., Collee, M. J., Peterlongo, P., ... Devilee, P. (2012). Rare variants in XRCC2 as breast cancer susceptibility alleles. JOURNAL OF MEDICAL GENETICS, 49(10), 618-620. https://doi.org/10.1136/jmedgenet-2012-101191
  20. Ding, Y. C., McGuffog, L., Healey, S., Friedman, E., Laitman, Y., Shani-Paluch-Shimon, N. V., ... Consortium Investigators Modifiers (2012). A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 21(8), 1362-1370. https://doi.org/10.1158/1055-9965.EPI-12-0229
  21. Spurdle, A. B., Whiley, P. J., Thompson, B., Feng, B., Healey, S., Brown, M. A., ... ENIGMA Consortium (2012). BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. JOURNAL OF MEDICAL GENETICS, 49(8), 525-532. https://doi.org/10.1136/jmedgenet-2012-101037
  22. Antoniou, A. C., Kuchenbaecker, K. B., Soucy, P., Beesley, J., Chen, X., McGuffog, L., ... kConFab Investigators (2012). Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast cancer research, 14(1), [33]. https://doi.org/10.1186/bcr3121
  23. 2011
  24. van Westrum, S. M. S., Hoogerwaard, E. M., Dekker, L., Standaar, T. S., Bakker, E., Ippel, P. F., ... van der Kooi, A. J. (2011). Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology, 77(1), 62-66.
  25. 2010
  26. Rijnsburger, A. J., Obdeijn, I-M., Kaas, R., Tilanus-Linthorst, M. M. A., Boetes, C., Loo, C. E., ... Klijn, J. G. M. (2010). BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology, 28(36), 5265-5273. https://doi.org/10.1200/JCO.2009.27.2294

ID: 124551